These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24217193)

  • 41. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.
    Thornton J; Ashcroft DM; Mughal MZ; Elliott RA; O'Neill TW; Symmons D
    Arch Dis Child; 2006 Sep; 91(9):753-61. PubMed ID: 16690698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bisphosphonates for osteoporosis--where do we go from here?
    Whitaker M; Guo J; Kehoe T; Benson G
    N Engl J Med; 2012 May; 366(22):2048-51. PubMed ID: 22571168
    [No Abstract]   [Full Text] [Related]  

  • 44. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness strategies to treat osteoporosis in elderly women.
    Pfister AK; Welch CA; Lester MD; Emmett MK; Saville PD; Duerring SA
    South Med J; 2006 Feb; 99(2):123-31. PubMed ID: 16509549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Benefits and risks of bisphosphonate therapy for osteoporosis.
    Khosla S; Bilezikian JP; Dempster DW; Lewiecki EM; Miller PD; Neer RM; Recker RR; Shane E; Shoback D; Potts JT
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2272-82. PubMed ID: 22523337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reasons for bisphosphonate exclusion in patients treated for osteoporosis.
    Kamneva O; Nye AM; Hamrick I
    Consult Pharm; 2011 May; 26(5):325-31. PubMed ID: 21733813
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD; Badamgarav E; Bauer DC
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Medical therapy of osteoporosis in patients with mildly to moderate decreased renal function].
    Eiken PA; Vestergaard P
    Ugeskr Laeger; 2012 Nov; 174(47):2926-30. PubMed ID: 23171789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The efficacy and safety of bisphosphonate for patients with kidney disease].
    Hiramatsu R; Ubara Y
    Clin Calcium; 2016 Sep; 26(9):1319-24. PubMed ID: 27561347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of osteoporosis in patients with chronic kidney disease.
    Gupta A
    Br J Hosp Med (Lond); 2014 Feb; 75(2):83-9. PubMed ID: 24521803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteoporosis in the elderly with chronic kidney disease.
    Ersoy FF
    Int Urol Nephrol; 2007; 39(1):321-31. PubMed ID: 17103030
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.
    Miller PD
    Curr Osteoporos Rep; 2005 Mar; 3(1):5-12. PubMed ID: 16036095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonate therapy in children with secondary osteoporosis.
    Papapoulos SE
    Horm Res Paediatr; 2011; 76 Suppl 1():24-7. PubMed ID: 21778744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antagonizing the calcium-sensing receptor: towards new bone anabolics?
    Riccardi D
    Curr Mol Pharmacol; 2012 Jun; 5(2):182-8. PubMed ID: 21787287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of osteoporosis in renal insufficiency.
    Schipper LG; Fleuren HW; van den Bergh JP; Meinardi JR; Veldman BA; Kramers C
    Clin Rheumatol; 2015 Aug; 34(8):1341-5. PubMed ID: 25630310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renal safety in patients treated with bisphosphonates for osteoporosis: a review.
    Miller PD; Jamal SA; Evenepoel P; Eastell R; Boonen S
    J Bone Miner Res; 2013 Oct; 28(10):2049-59. PubMed ID: 23907861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.